Australia TGA approves Iovance Amtagvi for previously treated advanced melanoma
PUBT · 1d ago
Share
Listen to the news
- Australia’s TGA granted conditional approval for Iovance’s Amtagvi (lifileucel) in previously treated unresectable or metastatic melanoma.
- Clearance covers adults who received prior PD-1 therapy; BRAF V600-positive patients must also have had BRAF-targeted treatment.
- Decision relied on Phase 2 C-144-01 data, supporting the company’s expansion into additional high-melanoma markets.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606031605PRIMZONEFULLFEED9731483) on June 03, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved